Group 1 - Libet has received approval from the China Securities Regulatory Commission for the issuance of convertible bonds, valid for 12 months [1] - Dinglong plans to acquire an additional 8% stake in its subsidiary, increasing its ownership from 91.35% to 99.35% for a total price of 240 million yuan [1] - Longyuan Donggu has been designated as a supplier for a major automotive project, with an expected total sales amount of 450 to 500 million yuan over five years [14] Group 2 - Luoniushan reported a sales revenue of 100 million yuan in May, a year-on-year decrease of 11.45% [2] - Baoming Technology has secured a loan commitment of up to 7 million yuan for stock repurchase [2] - Xinhua Pharmaceutical has received approval for the listing of a new chemical raw material used in treating chronic heart failure and hypertension [3] Group 3 - China Minmetals announced a new contract amount of 396 billion yuan for the first five months of the year, a decrease of 22.2% year-on-year [7] - Zhongbei Communication's application for a specific stock issuance has been accepted by the Shanghai Stock Exchange [8] - Rongfa Nuclear Power plans to issue bonds not exceeding 1 billion yuan to repay debts and supplement working capital [9] Group 4 - Phoenix Optical plans to invest 8.5 million USD to establish a wholly-owned subsidiary in Vietnam for manufacturing optical products [11] - Xiamen Airport reported a passenger throughput of 2.4752 million in May, a year-on-year increase of 8.34% [12] - Weilan Biological has received a new veterinary drug registration certificate for a product aimed at treating canine allergies and inflammation [13] Group 5 - Shouxiangu has completed the registration of a health food product that claims to enhance immunity [13] - Xingye Yinxin's subsidiary has passed a resource reserve verification report, confirming significant mineral reserves [16] - Shaanxi Construction has won two major projects with a total contract value exceeding 2.8 billion yuan [18] Group 6 - Huari received a cash dividend of 50 million yuan from its subsidiary [20] - Zhongchu's deputy general manager has resigned due to governance arrangements [21] - Kexin Pharmaceutical's core product has received breakthrough therapy designation from the National Medical Products Administration [39]

智通财经APP获悉，方正证券发布研报称，2024年以来国家大力推行低空经济规划发展，顶层与地方政 策共振推动相关规划不断完善，各省市明确基建规模、航线规划、应用场景、制造建设等目标，兑现期 从2025年至2030年不等。2025年将有望成为低空经济从前期规划转向产业落地的元年，而产业进入落地 阶段的前提则是相对完善的新数字基建布局，包括低空智联网、空管平台及外围设施、起降站点等。 应用端：无人机物流产业化将至，文旅/通勤场景打开新空间 2025年5月20日，发改委在新闻发布会上指出要按照先载货后载人、先隔离后融合、先远郊后城区的原 则，稳妥推进低空旅游、航空运动、消费级无人机等低空消费发展。同时，《交通物流降本提质增效行 动计划》指出要积极发展无人机配送等商业化应用。 目前美团第四代无人机通过民航局审查，获得全国首张低空物流全境覆盖运营合格证，头部厂商已开始 常态化运营。合肥、自贡、成都、上海、北京等城市已启用无人机进行低空医疗物品等物流配送，无人 机物流已成为目前最成熟的低空应用场景，巡检、测绘等相似的消费级低空无人机应用场景也有望加速 落地，对基建的需求将快速上升。在全国首个eVTOL运营许可证下发的背景 ...

证券代码：601901 证券简称：方正证券 公告编号：2025-022 方正证券股份有限公司 关于高级管理人员离任的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 根据相关法律法规及公司《章程》的规定，袁玉平先生的离任自辞职报告送 达董事会之日起生效。袁玉平先生已确认与公司董事会无任何意见分歧，且无任 何与离任有关的事项须提请公司股东注意，其辞去高级管理人员职务不会对公司 经营产生不利影响。 特此公告。 方正证券股份有限公司董事会 2025 年 6 月 11 日 公司董事会收到执行委员会委员、副总裁袁玉平先生递交的书面辞职报告， 袁玉平先生因个人原因申请辞去公司执行委员会委员、副总裁职务。 二、离任对公司的影响 一、高级管理人员离任情况 姓名 离任职务 离任时间 原定任期 到期日 离任原因 是否继续在上 市公司及其控 股子公司任职 具体职务 是否存在未 履行完毕的 公开承诺 袁玉平 执行委员会 委员、副总裁 2025 年 6 月 10 日 2026 年 6 月 7 日 个人原因 是 其他 否 ...

Group 1 - The core viewpoint of the news highlights the recent surge in the rare earth permanent magnet sector, driven by export control measures and market dynamics [1][2] - The A500 Index ETF (159351) has shown a positive performance, with a 0.62% increase and a trading volume exceeding 2 billion yuan, indicating strong investor interest [1][2] - The rare earth industry is experiencing a supply tightening and price stabilization, with expectations for moderate price increases benefiting equity sector profitability [2] Group 2 - The A500 Index ETF closely tracks the CSI A500 Index, which includes 500 representative stocks across various industries, balancing large-cap stocks with core industry leaders [2] - The A-share market is seen as having the potential for a bull market, driven by increasing household asset allocation towards equities and improvements in corporate governance and shareholder returns [3] - The overall profitability of Chinese enterprises is expected to rise, with a historical supply clearing cycle anticipated, indicating a shift towards higher value sectors [3]

Group 1: Investment Opinions on Innovation Drugs - Rongtong Fund's Wan Minyuan expressed skepticism about the innovation drug sector, claiming that most data pertains to 3-5 years in the future and that many companies are still in early clinical stages or preclinical, suggesting a significant bubble compared to previous CXO bubbles [1] - In contrast, a well-known private equity figure, "Chen Yingzhang," argued that the current wave of innovation drugs represents a historic reversal, with potential for leading companies to create world-class drugs and generate substantial wealth [1] Group 2: Mid-Year Strategy Meetings by Securities Firms - Major securities firms, including Huatai Securities and Guotai Junan, held mid-year strategy meetings, indicating a positive outlook for the A-share market in the second half of the year, with a consensus on the technology sector being favored [2][3] - Analysts from Huatai Securities noted that the valuation repair of Chinese assets is ongoing, with expectations that the A-share market will outperform overseas markets [2] Group 3: Investment Strategies and Opportunities - Guotai Junan's strategy chief highlighted a clearer "transformation bull" market in China, driven by policies aimed at debt resolution, demand stimulation, and asset price stabilization [3] - Investment opportunities identified include financial and high-dividend stocks, emerging technology sectors, and cyclical consumer goods, with a focus on companies with strong dividends and monopolistic advantages [4] Group 4: Company Developments and Financing - Shanghai Jiaqi, a quantitative private equity firm, underwent a change in actual control, with the new controller increasing their stake from 20% to 56%, indicating a strategic shift within the company [5] - Guoao Technology announced the completion of several million yuan in Series A financing, aimed at expanding production capacity and accelerating product development in high-end semiconductor and robotics sectors [5][6] - Shengwei Technology, a virtual machine developer, secured nearly 100 million yuan in funding to enhance its technology and market presence, contributing to the development of the domestic operating system ecosystem [7] Group 5: Strategic Partnerships and Initiatives - Renhe Pharmaceutical established a comprehensive strategic partnership with Western Securities, focusing on capital and industry collaboration to explore high-quality development paths [9] - China Merchants Securities launched the first ESG public financial laboratory and a public investment advisory fund, committing over 50% of advisory fees to charitable causes [10]

Group 1 - The core viewpoint of the strategy meetings is a positive outlook for the A-share market in the second half of the year, with a focus on the ongoing valuation recovery of Chinese assets and a preference for technology sectors [1][2][3] - Analysts from Huatai Securities emphasize the importance of China's economic development strategy in response to prolonged trade conflicts, which is expected to enhance consumer income and spending [2][3] - The consensus among various securities firms is that the A-share market is likely to outperform overseas markets, driven by a "transformation bull" market characterized by policy measures aimed at stabilizing asset prices and boosting demand [3][4] Group 2 - The technology sector is highlighted as a key investment focus, with analysts suggesting a "barbell" strategy combining dividend and growth stocks, while also considering opportunities in the consumer sector [5][6] - Citic Securities identifies three long-term trends: the enhancement of China's independent technological capabilities, the European focus on self-reliance in defense and resources, and the acceleration of domestic demand through improved social security [6] - The Hong Kong stock market is expected to benefit from the AI narrative, with analysts noting that the technology sector in Hong Kong is well-positioned to capitalize on the ongoing industrial transformation driven by AI advancements [7][8]

北京市朝阳区建外大街丁 12 号英皇集团中心 8、9、11 层 电话/Tel.:010-50867666 传真/Fax:010-56916450 网址/Website:www.kangdalawyers.com 北京 西安 深圳 海口 上海 广州 杭州 沈阳 南京 天津 菏泽 成都 苏州 呼和浩特 香港 武汉 郑州 长沙 厦门 重庆 合肥 宁波 济南 昆明 南昌 北京市康达律师事务所 关于方正证券股份有限公司 康达股会字 2025 第 【0280】号 致：方正证券股份有限公司 北京市康达律师事务所（以下简称"本所"）接受方正证券股份有限公司（以下 简称"公司"）的委托，指派本所律师出席公司 2024 年年度股东大会（以下简称"本 次会议"）现场会议。 本所律师根据《中华人民共和国公司法》（以下简称"《公司法》"）、《中华人民 共和国证券法》（以下简称"《证券法》"）、《上海证券交易所上市公司自律监管指引 第 1 号——规范运作》《方正证券股份有限公司章程》（以下简称"《公司章程》"）等 规定，就本次会议的召集和召开程序、出席会议人员和召集人的资格、会议的表决程 序和表决结果发表法律意见。 关于本法律意见书，本 ...

证券代码：601901 证券简称：方正证券 公告编号：2025-021 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并 对其内容的真实性、准确性和完整性承担法律责任。 公司第五届董事会第十五次会议于 2025 年 5 月 30 日以现场加视频的方式在公司 会议室召开。本次会议的通知和会议资料于 2025 年 5 月 23 日以电子邮件方式发出。 本次会议由董事长施华先生召集和主持，应出席董事 9 名，实际出席董事 9 名（施华 先生、姜志军先生、李岩先生、宋洪军先生、张忠民女士现场参会，张路先生、曹诗 男女士、林钟高先生、柯荣富先生视频参会），公司 3 名监事列席了会议。本次会议的 召集、召开程序符合《公司法》、公司《章程》的有关规定。 经审议，本次会议形成如下决议： 审议通过了《关于补选董事会专门委员会成员的议案》 董事会同意补选姜志军先生为董事会战略发展委员会委员、提名委员会委员。 方正证券股份有限公司 第五届董事会第十五次会议决议公告 主任委员：柯荣富；委员：姜志军、林钟高 表决结果：同意 9 票，反对 0 票，弃权 0 票。 特此公告。 方正证券股份有限公司董事会 ...

2024年年度股东大会决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 本次会议是否有否决议案：无 一、 会议召开和出席情况 （一）股东大会召开的时间：2025 年 5 月 30 日 证券代码：601901 证券简称：方正证券 公告编号：2025-020 方正证券股份有限公司 （五）公司董事、监事和董事会秘书的出席情况 （三）出席会议的普通股股东和恢复表决权的优先股股东及其持有股份情况： | 1、出席会议的股东和代理人人数 | 1,522 | | --- | --- | | 2、出席会议的股东所持有表决权的股份总数（股） | 4,349,705,043 | | 3、出席会议的股东所持有表决权股份数占公司有表决权股 | | | 份总数的比例（%） | 52.8383 | （四）表决方式是否符合《公司法》及《公司章程》的规定，大会主持情况等 （二）股东大会召开的地点：北京市朝阳区朝阳门南大街 10 号兆泰国际中 心 A 座 19 层会议室 1、公司在任董事8人，出席8人； 2、公司在任监事3人，出席3人； ...

北京市朝阳区建外大街丁 12 号英皇集团中心 8、9、11 层 8/9/11/F, Emperor Group Centre, No.12D, Jianwai Avenue, Chaoyang District, Beijing, 100022, P.R.China 电话/Tel.:010-50867666 传真/Fax:010-56916450 网址/Website:www.kangdalawyers.com 北京 西安 深圳 海口 上海 广州 杭州 沈阳 南京 天津 菏泽 成都 苏州 呼和浩特 香港 武汉 郑州 长沙 厦门 重庆 合肥 宁波 济南 昆明 南昌 本所律师根据《中华人民共和国公司法》（以下简称"《公司法》"）、《中华人民 共和国证券法》（以下简称"《证券法》"）、《上海证券交易所上市公司自律监管指引 第 1 号——规范运作》《方正证券股份有限公司章程》（以下简称"《公司章程》"）等 规定，就本次会议的召集和召开程序、出席会议人员和召集人的资格、会议的表决程 序和表决结果发表法律意见。 关于本法律意见书，本所及本所律师谨作如下声明： （1）在本法律意见书中，本所律师仅就公司本次会议的召集和召开程 ...